GSK gets FDA nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

from Reuters: Health News https://ift.tt/2JerMGj